Akèy › Kansè vejik › Ohio › Columbus
Etid klinik pou Kansè vejik nan Columbus, OH
19 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- ak 8 plis
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Ap rekriteFaz 2
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- ak 1 plis
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- ak 11 plis
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Ap rekriteFaz 1
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · 7 mi lwen
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- The Ohio State University (OSU), Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Ap rekriteFaz 1/2
- Central Ohio Urology Group, Gahanna · 7 mi lwen
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Ap rekriteEtid obsèvasyon
- The Ohio State University, Columbus
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Ap rekriteFaz 2/3
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Ap rekriteFaz 2
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- ak 2 plis
Blue Light Cystoscopy With Cysview® Registry
Ap rekriteEtid obsèvasyon
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Columbus
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Boston, MA26 etid
- Washington, DC26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Philadelphia, PA21 etid
- Seattle, WA21 etid
- Edison, NJ21 etid
Lòt etid nan Columbus
- Kansè Poumon ki pa ti selil56 etid
- Kansè nan tete39 etid
- Kansè ovè39 etid
- Kansè (tout kalite)38 etid
- Kansè poumon37 etid
- Leksemi mieloïd egi35 etid
- Lukemi lenfositè kwonik28 etid
- Kansè Metastatik27 etid
- Kansè Endomèt25 etid
- Kansè kolorektal24 etid
- Kansè pwostat24 etid
- Myelom Miltip24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.